← Leaderboards
Daniel R Scoles
Utah State Higher Education System--University Of Utah
$6,542,278
Attributed
$9,779,691
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,779,691 · 10
By mechanism
R01$4,194,681 · 2
U01$1,923,997 · 1
R21$1,672,359 · 4
RC4$834,912 · 1
R33$769,994 · 1
R61$383,748 · 1
Top collaborators
- Stefan M. Pulst11 shared
- Meera Pratap3 shared
- Mariana Mandi Gandelman1 shared
Most similar at Utah State Higher Education System--University Of Utah
Same institution · by research overlap
- Stefan M. Pulst$18,000,219
Others in their field
Top investigators on “Mouse Model”
- Dennis R. Burton · Scripps Research Institute$280,661,242
- David Heimbrook · Leidos Biomedical Research, Inc.$84,491,283
- Kc Kent Lloyd · University Of California At Davis$74,285,556
- Alan F Horwitz · University Of Virginia Charlottesville$73,668,592
- Stanley B Prusiner · University Of California San Francisco$61,905,394
- Ed Lein · Allen Institute$59,425,748
Research focus
Mouse ModelNerve DegenerationNeurodegenerative DisordersProteinsPhenotypeGenesAmyotrophic Lateral SclerosisMotorType 2 Spinocerebellar AtaxiaProtein Tdp-43NeuronsCellsPathway InteractionsPurkinje CellsMolecular PhenotypeIn VitroMutantAffectMolecularPolyglutamineIn VivoTransgenic MiceAutophagocytosisMalignant Neoplasms
Grant awards (22)
PASK-regulated genes and proteins as therapeutic targets for ALS and FTD$764,464
R01 · FY2025 · NS · contact PI
Targeting STAU1 for TDP-43 proteinopathies$384,997
R33 · FY2025 · NS · contact PI
PASK-regulated genes and proteins as therapeutic targets for ALS and FTD$752,319
R01 · FY2024 · NS · contact PI
Targeting STAU1 for TDP-43 proteinopathies$384,997
R33 · FY2024 · NS · contact PI
Regulation of paraspeckles by STAU1 in neurodegenerative disease$231,000
R21 · FY2024 · NS · contact PI
Investigation on Ataxin2 and Matrin3 in neurodegenerative disease$422,125
R21 · FY2023 · NS · contact PI
Regulation of paraspeckles by STAU1 in neurodegenerative disease$192,344
R21 · FY2023 · NS · contact PI
Targeting STAU1 for TDP-43 proteinopathies$383,748
R61 · FY2022 · NS · contact PI
RNA Granules in Cerebellar Neurodegeneration$452,836
R01 · FY2021 · NS · contact PI
Antisense Oligonucleotides for treating Spinocerebellar Ataxia Type 2$743,700
U01 · FY2020 · NS
RNA Granules in Cerebellar Neurodegeneration$454,923
R01 · FY2020 · NS · contact PI
Antisense Oligonucleotides for treating Spinocerebellar Ataxia Type 2$590,956
U01 · FY2019 · NS
RNA Granules in Cerebellar Neurodegeneration$456,978
R01 · FY2019 · NS · contact PI
Characterization of ATXN2 as a target for ALS in SCA2 motor neurons$228,750
R21 · FY2019 · NS
Antisense Oligonucleotides for treating Spinocerebellar Ataxia Type 2$589,341
U01 · FY2018 · NS
RNA Granules in Cerebellar Neurodegeneration$458,997
R01 · FY2018 · NS · contact PI
RNA Granules in Cerebellar Neurodegeneration$381,052
R01 · FY2018 · NS · contact PI
Characterization of ATXN2 as a target for ALS in SCA2 motor neurons$190,625
R21 · FY2018 · NS
RNA Granules in Cerebellar Neurodegeneration$473,112
R01 · FY2017 · NS · contact PI
Antisense oligonucleotides for the treatment of spinocerebellar ataxia type 2$221,265
R21 · FY2014 · NS · contact PI
Antisense oligonucleotides for the treatment of spinocerebellar ataxia type 2$186,250
R21 · FY2013 · NS · contact PI
Drug Discovery for Spinocerebellar Ataxia Type 2 (SCA2)$834,912
RC4 · FY2010 · NS